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Between January 1. 1989. and December 31. 1994. we bave treated-t22 
primary beart recipients with FK 506 (group I) and 121 ~ith cyclosporine 
(group m. Fifty patients in tbe cyclosporine (CyAl group received no 
lympbolytic induction EC~A alone I and 71 others received Iympholytic 
induction with either rabbit antitbymocyte globulin or 01\.13 (CyA+U). 
The mean follow-up was longer in tbe FK 506 group tban in the CyA groups 
(3.2 :!: 1.3 vs 2.3 :t 1.8 years: p < 0.01). Patient survival did not dilfer on tbe 
basis of the type of immunosuppression used. At 3 months after transplan-
tation. the freedom from rejection in the FK 506 group was higher than tbat 
of tbe CyA-alone group (47% vs 22%, p < 0.01) but similar to that of the 
CyA+U group (47% vs 53%). The linearized rejection rate (episodes/tOO 
patient-days) of the FK 506 group (0.09 episodes) was lower (p < 0.05) tban 
tbat of the CyA-alone group (0.26) and the CyA+U group (0.13). The 
requirement for pulsed steroids to treat rejection was less in common in tbe 
FK 506 group than in eitber CyA group. Eighteen patients in the CyA group 
had refractory rejections: all resolved with FK 506 rescue. Two patients in 
the FK 506 group had refractory rejection that resoh'ed with totallympboid 
irradiation (n = 11 and methotrexate therapy (n = 1). Patients receiving 
FK 506 bad a lower risk of hypertension and required a lower dose of 
steroids. Altbough the mean serum creatinine concentration at 1 year was 
higher in the FK 506 group. this dilference disappeared after 2 years. No 
patients required discontinuation of FK 506 because of its side effects. Our 
intermediate-term results indicate that FK 506 compares favorablv with 
CyA as a primary immunosuppressant in heart transplantation. (J THORAC 
CARDIOVASC SURG 1996:111:764-72) 
Tacrolimus (FK 506). a macrolide lactone derived from the fungus Screptomvces csurobaensis. was 
recently approved by the Food and Drug Adminis-
tration for use as an immunosuppressive agent in 
liver transplantation. In vitro FK 506 has been found 
to be lLl to 100 times more potent than cyclosporine 
(CyA I in its immunosuppressive prooerties. I.:! We 
first introduced FK 506 into clinical heart transplan-
tation In October 1989 and have since treated 122 
primary heart recipients with this drug. This report 
summarizes our 5-year experience \\;th the use of FK 
506 as a primary immunosuppressant in heart trans-
plantallon. We will compare the clinical outcome of 
heart recipients treated with FK 506 with that of a 
concurrent cohort treated with a C~AK-based regimen. 
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Patients and methods 
Patient population. The pauent population in this 
'>Iud\' ':l)nSISICU (\1 p:lt!ents wno had :lll miual heart 
tranSplantaUon and sUIVlved lor more than 7 days alter 
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transplantation. P:.Itients who had st!cond transplants or 
multiplt! organ transplants or who dit!d within 7 davs atter 
transplantation because or primary graft failure wert! 
t:xcluded from the anaivsis. 
Between J anuar\, I. i 9~9K and December 31. 1l}94. 2.+3 
ht!art transplant reCipients at our center met these criteria. 
.-\ total of 122 patients received an FK 506-hased immu-
nosuppression protocoi. and 121 were treated With a 
CvA-hased regimen. From Januarv to September. 1989 all 
patients received CvA-based immunosuppression. When FK 
506 was available tor clinicai trial in heart transpiantatlon at 
our center in October 1989. all heart transplant recipients 
were considered as potential candidates for the FK 506 
protocol. CyA was used only when informed consent could 
not be obtained or when there were restrictions trom third-
partY payers on the use of experimental drugs. 
The use of FK 506 was approved by the Institutional 
Review Board at the Cniversitv of Pittsbureh. and in-
formed consent was obtained from every patient. 
The demographic data tor these patients are summa-
rized in Table I. The FK 506 group had a lower mean age 
than the CvA !!fOUO (3'+.2 ::: 22.3 vs 47.8 ::: 14.5 vears: p < 
(LOS). The'mean duration of follow-up was longer in the 
FK 506 group (3.2 :: 1.3 vs 2.3 == 1.8 years: p < 0.01). No 
sieniticant difference was observed in the mean ischemic 
ti;;'e between the C\'.-\ (:06.9 = 63.2 minutes) and the FK 
506 groups (215.1 ~ 63.2 minutes). 
Immunosuppression protocols. In the FK 506 (Pro-
~ratKyK F u i isawa L SA. Deerrield. Ill. I. group til = 122). 
patients were given methvlprednisolone in a uose ot IS 
mg; kg during the llperanon . .:i mg;kg per dav in three 
Jivided doses on postoperative day I. and U.3 mg.'kg per 
Jay as a single dose thereatter. Methylprednisolone was 
ulnverted tl1 preomsone when the patient was able to 
tllierate a diet. anu weamne trom sterOids was begun 2 
[llonths alter transmlantatlo~K In the early pnase l;r this 
,[udv. FK :,lJ6 \\as aummistereu 6 to 12 hours atter 
[ranSplantallon. ~lI .1 -K:~Dse Llt 11.1:' mg.'Kg per Llav in rwo 
Jivided doses. each over ~ hours. tor a duration ot 2.+ to 72 
!lllurs. l3eC:lUse rcnal LlhtunCllOI1 was prevalent with thiS 
!'t:Ulmen. \\e lu\'e mllLllried this protocol. Since .-\Ugust 
I '}l}O, FK SOh has neen ~fven Intravenouslv at a dose III 
II,OS mg.-kg pt:r Ua\' ilS a c'llntinuous infUSion 0 t(1 12 hours 
.llter transplantation .. -\' soon as (he patient's gastromtes-
tlnal !unctlon rt:lUrneu. ,lrai FK S06 was commenceu at a 
Jllsal,!e ot 11.2 tll II .• ; m~ "g per uav in [WO diVided uoses. 
fhe plasma Ic\ei 11':·hllur trough = n.S III 2.0 ngmil has 
heen replaced [1\ il \\ nllie hlond FK Silo level.' yy~hich was 
mamtamed a( :- Tll .;1) ng ml. In the tirst 2 months atter 
transpiantatlon. The FK -,llo level was kept in the ranue of 
1:- (0' ,,() ngml. This ie\cl was gradually decreased (o':'i to 
15 m!/ml accoruinu III tne pattern or' reiecllon and the 
,latus 01 the renaC tum:non .. \Lathiopnne (2 mg.kg pt:r 
,Iav) was auded It the ,erum creatinint! level was hiuher 
than 2.0 mg/ul t to ailL)\\' a reduction in the FK 5Uh dt)s;ue I 
llr II there 'was perststent releCtlon. When a .:ombinatlon 
"t FK SOb. stcwlds. anu azathloprme was reuuired. enuo-
myocardial biopSies \\ere perIormed monthlv. anu pa-
IIt:n[S havt: [lcen il:K::K:n:s~lvelv weaned from steroids II'v :' 
Ill!! per month I tll .1\ lllU malor tnlectlons. 
fhe ImmunllSUPOreSSH1I1 nrot(1col for <. ·v.-\ nius Ivmnno-
,\lIC dlLiUdllll\ ,,-\,\-i1.·: -II \\1[11 ,:::1c:r lFhq~ 
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Table I. Demographics of cardiac transp/ar: 
recipients receiving FK 506 and ~vA 
No. of pallents 
Age (yr, 
Mean = SD 
Range 
<ISH 
> 18 yr 
Gender 
Male 
Femaie 
Underlying disease 
Ischemic 
Idiopathic 
Congenllai 
Other 
IschemiC ume (min) 
Mean = SD 
Durallon or iollow-up (yr) 
Mean = SD 
SO. Standard deviation. 
'p < 0,05. 
7p < 1'-01. 
immunosupprtSSlOn 
FK 50n evA 
122 121 
34,2:: 22.3 -!7.il :: 14.5" 
0-65.2 1.8-66.3 
-!2 lOt 
/jl! ill 
97 104 
25 17 
37 53 
31 -!9 
27 3 
27 16 
21S.1 = 63.0 :06.9 :: 63.2 
3.2 :: 1.3 :.3 :: 1.9t 
(Orthoclone. Ortho Pharmaceutical Com .. Raritan. N.J.) 
III = III or rabbit antithvrnocyte globulin IATG: n = 60) 
has been described in details elsewhere." A TG was pre-
;Jared localiv bv Dr. Charles p, Bieber according to the 
method or Davis. Cooperband. and ManmcK.o In this 
iJrotocol. -:croids were administered as previouslv de-
,cribed ior tne FK 506 group. AzathlOpnne 14 mg/kg) was 
~fgministerea intraoperatively and connnued postooera-
tivelv at a aosage oi 2 mg/kg per day so long as the white 
hlood ceil count was greater than 3500 ceilSlmm-. CYclo-
-ponne was started within 24 hours alter the operation. 
itnd the target troul,!h whole blood level was mamtamed at 
,00 to 1200 n!!iml (TDx method. Sandoz Pharmaceutical 
Corp.. East Hannover. N.J .1. 0 KT3 was aammistered 
!ntrayenlr~ls at 5 mg;dav tor 14 Javs begmnine on the 
't:cond or ([lird postoperative Jay. ~nd ,.\TG w-as given 
intramUSCUlarlvat 1.5 mg/kg per dav dunng the rirst:; days 
.liter the transplantation. 
[n the !!roup receiving CyA without l,mpholvtic induc-
t illO (C\,-\ .llone I (1/ = :'Ol, a modi tied triple drug regimen. 
;IS prevIous IV described by Bolman and assoclate;.7 was 
used. In lmet. a preoperative loading uose or C.'yA (6 to to 
lng/kg) was administered orallv 2 hours heiore the oper-
~y!fonK On postoperative day I. oral CvA was commenced 
twice a dav at appropriate dosages (2 to () m~/kg per dayl 
III mamtam a trough whole blood (TDx method. Sandoz) 
k:ve1 ot SilO to 1200 nglm/. Methvlpreomsolone at a dose 
lIt 15 mg. h~ was given dunng the opt!ranon. ILlllowed by 3 
:l1g;kg per dav in tour divided doses on postoperative day 
I. and reouced to 0.4 mg/kg per dav tw postoperative day 
., '\leth\'lurednisone was converted to predmsone on the 
. c'[urn l'f K~;: \,!i\strllll1leSl1nal tunctH1n, r)" I m(lnlh alter 
7 () () Pham et ai. 
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Fig. L Actuarial survival of cardiac transplant recipients according to different immunosuppression 
protocols. 
transplantation. the dose of prednisone was reduced to 0.3 
mg/kg. and steroids were weaned further after 6 months. 
Azathioprine was administered as in the CyA~if group. 
Monitoring for rejection. Surveillance for reJection in· 
volves weekly endomyocardial biopSIes during the tirst 
month. monthly for the next 3 months. and every 3 months 
for the remaining tirst year. Thereafter. biopSIes are 
performed semiannually. In addition. endomvocardial bi· 
opsies are performed whenever clinically indIcated. In 
infants and small children. endomyocardial biopsies are 
performed less freouently because of the inherent techni· 
cal difficultv. Biopsv specimens are graded according to 
the criteria of the International Societv for Heart and 
Lung Transplantation.' . 
Treatment of rejection. Acute reiection (grade 3A or 
higher) IS treated v.ith boluses of methylpreonIsoione (1 
grrt/day for adults and 10 to 20 mg/kg per day for pediatric 
patlents. tor 3 days I. Grade 1 B to 2 re1eCtlOnS are treated 
by augmenting the baseline doses of the pnmarv immu· 
nosuppressant (FK 506 or CyA) or steroids. OKT3 or 
ATG is reserved for steroid·reslstant rejections. 
Monitoring for infection. Pretransplantauon titers ior 
herpesvirus. hepatltls A. B. and C viruses. and Toxoplasma 
c;ondii were obtamed on every patient. After transplanta· 
tion. all patients were lollowed up by an infectiOUs disease 
specialist. Infections were diagnosed according to previ-
(luslv established cnteria." Onlv maior infections. as pre· 
viously denned." that necessItated hospltalizatlon tor m· 
travenous drug therapy were included for analvsis. 
Statistical analysis. Actuanal survival. ireedom trom 
;lcute rejection. and freedom from allogratt coronarY 
;lrteriopathy were computed bv means of life table anal· 
vsis. These analvses were based on both the Intention-to· 
ireat method (data were analvzed according to the initial 
treatment ;lsslgnment) and the \:cnsonng \:rosSO\'C, 
method (crossover.; were \:ensored when treatment 
changed). ,,' II SUTVI\'al curves were comparell b\' means 
of the log·rank IMantel·Cox) test. Differences ID group 
means were comDared hv the [ rest. ~Inu ~fnalyIs!s ,11 
variance for repeated measures with adjustment was made 
for compansonwise errorKl~ Differences in proportions 
were compared by the i" test. A p value less than 0.05 was 
considered statistically signiticant. For the calculation of 
incidence rates Eepis~des~ per 100 patient-days) of rejec-
tion. infection. requirement for steroid bolus. and lympho-
lytic treatments at patients in the CyA group who were 
converted to FK 506. the rates were calculated from the 
time of the transplantation to the time of conversion to 
FK 506. Incidence rates were compared with the use of 
the two-sample test for incidence-density measure. i3 A 
sonware package (CSS Slatistica. Release 4.5. Statsoft. 
Tulsa. Okla. I was used for statistical analvses. 
Results 
Patient survivals. According to the intention-to· 
treat analysis. the 1- and 5·year actuarial patient 
survivals did not differ significantly on the basis of 
the type of immunosuppressive protocols (CyA 
:llone. 91 CC and 74%: CyA + LI. 93CC and 69%: FK 
506. 90t( and 76%) (Fig. 1). Because the intention-
to·treat analyses have been criticized for not evalu-
:lting the true effect of the treatment in studies in 
which there are significant crossovers (I5SG of pa· 
tients recelvmg CyA initially were converted to FK 
506 r see below 1). we have analvzed the survival data 
llStn£ ooth the intention-to-treat and the censoring 
cros~oyDer methods. 10. II In the former method. data 
:lre anaivzed according to the initial treatment as-
signment: in the latter, data are censored when 
there is :l change in treatment (crosso\'erl. There 
\vas no difference in patient survivals according to 
the types of immunosuppressive protocols when 
either method was used. 
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Causes of death. Twenty-four patients In the FK 
506 and 23 in the CyA groups (CyA alone and 
CyA.,... LI) died during this study (p = not signiricant: 
Table Il). The most common causes of death for 
both groups were rejection and infection. Three 
patients died of disseminated posttransplant Iym-
phoproiiferative disease, one in the FK 506 group 
and two in the CyA group. Four patients in the CyA 
group died of other malignancies including lung 
tumor (n = 1), testicular tumor (n = ll. osteosar-
coma In = I), and recurrent cardiac rhabdomyosar-
coma (n = 1). 
Acute rejection. The actuarial freedom from re-
jection at 3 months for the CyA-alone group was 
22%. significantly lower (p < 0.01) than that of the 
CyA+LI (53%) and FK506 groups (47CC) (Fig. 2). 
The incidence rate of rejection (episodes per 100 
patient-days) in the FK 506 group was significantly 
lower Ip < 0.05) than that of the CyA-alone or 
CyA + LI group (Table III). Steroid boluses used to 
treat rejection were lower in the FK 506 group than 
in the CyA-alone (p < 0.01) and the CyA + LI (p < 
0.05) groups. There were fewer rejection episodes 
that necessitated lympholytic treatment in the FK 
506 group than m the CyA-alone group IP < 0.01). 
Intractable rejection. Thirteen patients in the 
CyA-alone group and five in the C~A-if group 
(four with ATG and one with OKT3) had refractory 
rejeCtIon that was resistant to conventlonai therapy 
with at least one course of pulsed steroids and one 
~ourse at lvmpholvtic treatment. All 1;) at these 
patients were successfully treated by conversion to 
FK SOn. OnlY two pediatric patients in the FK 50n 
group had retractorv reiection. One reqUIred total 
lvmphoid irradiation and the other \\as treated 
'iuccessfullv with methotrexate. 
AlIo2rat't coronary arteriopathy. Allograft coro-
nary artenopathy atter transplantation \\ as l1ctined 
~lp an\' lummal irregularity and an\' coronar\' stenosis 
,een un the ~oronarv angIogram or ,lnv dilfuse 
~oronary artery disease at autopsy. In IS3 patients 
whose allogrart coronary arteries ~ould be evalu-
ated. the actuarIal freedom from allogran coronarY 
artenopathy at of years ror the FK 506 ( 103 patients) 
and eyA (80 patients) groups was s.::re and 73q.. 
respectively (p = not significant) (Fig. 3). 
Requirement for steroids and azatbioprine. At 
most recent follow-uo examination llr at the lime of 
death .. +0 of (")3 adults receiving FK 50b I-+SCc) were 
trce lit steroIds as ~ompared with 10 or 95 adults 
receIving evA ( 17re) (p <-. (I.t) 1), .-\mong those who 
were sull receIving stermos. the J\t:rage uativ dose 
Pham et al. 7 6 7 
Table II. Causes of death during FK 506 and (vA 
immunosuppression 
Immunosuppression 
FK 5fJ6 C:vA 
:-.10. oi patients 122 121 
No. oi aeaths 2-l (20':1) 23 (19%)' 
Causes oi death 
Acute rejection 2 (2%) 4 (3%) 
Allograft CAD 3 (2':1) 5 (4%) 
Infection tJ(5':1) 3 (2%) 
~alignancy 
PTI.D 1 (0.8%) 2 (2%) 
Others 0(0%) 4(3%) 
~tisceilaneous 12 E1M~F 7 (6%) 
CAD. Coronarv anery disease: PTLD. posnransplant Iympboproliferative 
llisease. 
'p = Not SlgruJicant. 
of prednisone was 5.8 :!:: 2.6 mg in the FK 506 group 
and 8.0 = 4.5 mg in the CyA group (p < 0.01). The 
most significant impact of FK 506 has been in the 
pediatric patients: 76% of the 42 pediatric recipients 
treated \\ith FK 506 were free of steroids. Of the 10 
pediatric patients (age = 1.8 to 17 years) who were 
initially given CyA. eight required conversion to FK 
506 because they could not be weaned from steroids: 
all of these were eventually free of steroids. 
AzathIoprine was added to the steroidJFK 506 
regimen when serum creatinine concentration was 
higher than 2 mgJdl or when there were at least two 
..:onsecuuve episodes of acute rejectlon that neces-
sitated treatments. At latest follow-up. 43% of pa-
tients receiving FK 506 were also receiving azathio-
pnne. 
Infection. A total of 70 episodes 10.05 episodes 
per 100 oatient-davs ) of major infections occurred in 
the FK S06 group as compared with 59 episodes 
I. (J.06 eplSodes per 100 patient-days) in the evA groups 
Ip = not significant), The prevalence of bacterial. viral. 
,!nd fungal infection was not sigmricantly different 
between me FK 506 and CyA groups. 
~epbrotoxicityK The effect or FK 506 on renal 
function was most pronounced during the first year 
after tr:msplantation in both adult and pediatric 
patients. inasmuch as the mean serum creatinine 
~oncentration was much higher (p < 0.01) after the 
nrst year I adult = 2.1 ::: 0.5 mg;dl: pediatric = 0.9 ::: 
n.5 mg 01) when compared with the pretransplanta-
tion vaiues (adult = l.l ::: U.5 mgJdl: pediatric = 
0.6 = '1.3 mgJdl). The rise in serum creatinine 
concentration leveled off after the rirst postopera-
live ye;lr. In the ;lJult patients (;lge > l S vears I mean 
7 61' Pizam et al. 
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Fig. 2. freedom from acute rejection I grade 3A or higher ~ according to different immunosuppression 
protocols. The actuarial freedom from rejection in patients wilo received triple-drug therapy without 
lympholytic induction (CyA alone~ was iower (p < 0.01) than that of the FK 50b group. :\0 difference in 
the freedom from rejection berween the FK 50b-treated patients and the CyA-treated patients who 
received Ivmphoiytic induction. 
Table III. Reiection. and requirement (or steroid 
boluses and lvmpholvtic treatments under different 
protocols 
fmmunosuporeSSlOn 
FK 506 
Rejection-tree rate at 3U days ·.l7""r 
Episodes of releCllon I !'<o. ~K 0.09 
Steroid bolus INo.I' O.OY 
LvmpholvlIc treatment I No.)' Il.OOY 
D~umber per IIJU palIenl-Oa\s. 
"(' < flill compared with FK SOb group 
.p < 0.U5 compareo with FK SOb group. 
CIA 
22l{7 
0.26" 
il.20= 
11.007 
53r-c 
11.l3:j: 
lUI :t 
1J.02 
serum creatinine levels at 1 and 2 yearS aner trans-
plantation were higher in the FK 506 group than in 
the CyA groups (Fig. -I). However. this difference 
did not reach statistical significance (by tne analvsis 
of variance for repeated measures,. 
Renal failure necessitating dialysis or kidney 
transplantation developed in five patients In the FK 
5U6 group and in seven in the CyA groups 2 to .5 
years after transplantation. In the CyA groups. three 
patients required dialysis while being treated with 
CyA alone and tour required dialysis ~ftcr being 
converted to FK 506. Of these tour patients 
..,wltched to FK 5Uo. two had intections I Gnt! mucor-
mycosis and one tuberculosis) that necessitated an-
tibiotics with nephrotoxicity. 
Other side effects 
H'penension. The prevalence of new-onset hy-
penension in adults in the FK 506 and CyA groups 
was -lice (39/83) and 84% (80/95). respectively (p < 
0.Dl\. In the pediatric group. 10% of the patients 
treated with FK 506 had hypertension. 
Hvperka/emia. Twenty-five adults and one pediat-
ric patient (21 0C) who were receiving FK 506 had 
persistent hyperkalemia (K- >5.0 mEqjL) that ne-
cessitated treatment. This was easily controlled with 
a low dose of ftudroconisone (0.2 mg;day). No 
patient died of hyperkalemia in this trial. 
DiaDeres meiiillls. The prevalence or new-onset 
insulin-dependent diabetes mellitus was the same in 
adults in both the FK 506 (260) and CvA (22o/c) 
groups. ~ew-onset insulin-dependent diabetes mel-
litus developed in one of SO pediatric patients 
recei\'Ing FK 506 (both as a primary agent and after 
conversion from CyA). 
Posrrrallsplalll IvmphoproiIterative disease alld 
other maiirmallt diseases. Posttransplant Iymphopro-
literatlve disease developed in two pediatric patients 
in the FK SOh group at -I and 5 months after 
transolanration. In one patient the disease resolved 
With reduction In immunosuppressIon: the other 
The Joumal of ThoracIc ana 
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Fig. 3. Actuanal freedom from allogran coronary artery disease (em) in patients who received FK 506 
versus those who received CyA-based regimen twith and without j~mpholytic induction}. No difference was 
observed between the two groups tp = 1l.U7). 
patient died of disseminated posttranspiantation 
lymphoproliferative disease. Another pediatric pa-
tient. who initially received CyA. died or dissemi-
nated posttransplantauon lymphoproliierative dis-
ease after conversIOn to FK 506. Of the adult 
patients. one in the CyA group died or brain lym-
phoma: four in the CyA group died of other malig-
nancies. including osteosarcoma til = i I. recurrent 
(ardiac rhabdomyosarcoma (II = 1). lung -:arcinoma 
(11 = It and testicular embrYonal cdl c:1rcinoma 
(II = I). 
Other side etfects 01 FK 506. which have been 
I".:ported dsewherc' o ::nd included extremItv pares-
theSIS. akinetic mutISm. mvalgia. and trcmor. \vere 
illtr.:qul!nt anu tDnslent. :--Jotabh' ~lrDcnt in the 
FK 500 group \\ere ~in~ival hyperpiasla. hirsut-
i~mK and coarsenIn£ of facial features. \l) patients 
- . 
in the FK 5Ub ~roup had severe Jnu oersistent 
,ldverse events th;H required discontInuation of 
thiS drug. 
Discussion 
.-\Ithough chemlcallv unrelated. FK .".)('1 and CvA 
hoth inhibit the Immune response via theIr abilitv to 
prevent the transcrlotlon ot Iymphokine ::enes alter 
t he activation ot T--:ct1 receptorsKl~ Both Jct earlv in 
the cdl cvc\e and thus are verY edectl\c as immu-
. . 
Ilosuppressants. Since its discover.' h\' Ochia and 
;lssociates 1.' in flj~TK FK 506 has been extenSively 
'ludied. In vitro. FK SUb suppressed thc prolifera-
I in: response in mixed hmphoc\'te cultures hv in-
:lihitmg fnterieukfn-~ ,\nthesls .llter .ilioactlva-
tion.l.:' ;, In vivo, FK 506 effectively prevented and 
reversed rejection to various allograits in different 
animal models. 16- 18 FK 506 was initially introduced 
into clinical use in 1989 by Starn and'colleagues19 
for the treatment of liver. kidney. and pancreas 
recipients. After the initial success of FK 506 as a 
primary and rescue agent in clinical organ transplan-
tation.:'-::":: randomized multicenter trials both in the 
Cniled 5::ltes and in Europe with liver transplant 
recipients have indicated that FK 506 is effective and 
superior to CyA as an Immunosuppressive 
agent. ':":-:.5 FK 506 was finally approved by the Food 
and Drug Administration for use in clinical liver 
transplantation in 1 YY4. We tim mtroduced FK 506 
into clinical heart transplantation In October 1989. 
Our initial experience with this drug as a primary 
and rescue agent indicated that FK 506 was an 
edective :mmunosuppressant and was well tolerat-
ed:' Thc Intermediate-term data reported herein 
(ontirm L1ur initial tindings. Although the sUfVIval is 
the same In both groups. an FK 5U6-based regimen 
results ::1 a lower rate of acure and retractorv 
rejection rnan does a CvA regimen. The effect of FK 
506 was most pronounced when it was compared 
with a L\.\-based regimen that included no lympho-
lytic induction. In addition. FK 506 was associated 
with a 1L1Wer risk for hypertension and fewer requlre-
ment for steroids. 
The tact that 15% of the patients in the CyA 
groups \\cce successtully converted to FK 506 for 
refractory rejection retlects. in part. the more potent 
Immunosuppressive properties ot FK 506 and. in 
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Fig. 4. Serum creatinine levels at various time points after transplantation in adult cardiac recipients 
receiving FK 506 and CyA. One year after transplantation. the serum creatinine levels were significantly 
higher than the pretransplant (PreTxJ values for both groups (p < 0.01). There were no statistically 
significant difference in the serum creatinine concentrations between FK 506 and CyA groups. 
part. our philosophy to minimize the use of multiple 
courses of high-dose steroids and lympholytic ther-
apy. In our earlier experience with F1\. 506 as a 
"rescue" drug for refractory rejection. we observed 
a very high incidence of posttransplantation lympho-
proliferative disease. especially in patients who had 
received multiple courses of steroids and lympho-
lvtic agents before being converted to FK 506.2b 
Excessive use of l~mpholytic treatments is a primary 
risk factor in the development of posttransplanta-
tion lymphoproliferative disease.27 We therefore 
strongly believe that early conversion to FK 506 in 
patients with refractory rejection who are being 
treated with CyA should reduce this risk. 
Renal toxicity 1S a major side erl'ect of borh FK 506 
and CyA. Studies in liver recipients have shown that 
nephrotoxicity was comparable between CyA and 
FK 506 and that the mean serum creatinine levels at 
vanous time points after transplantation were simi-
lar in the two groups. 23. ~R In the current study. I 
year atter transplantation. patients in the FK 506 
group had slightly higher mean serum creatinine 
levels than those in the CyA group IP = not 
significant). However. this difference disappeared 
after 2 years. The higher serum creatinine level at I 
year after transplantation in the FK 506 group 
probablv reflects our learning curve in the use of this 
drug. With expenence. we believe that this differ-
ence will disappear. Hyperkalemia is a known side 
effect of FK 5U6 and has been reponed to be 
independent of renal function. 2s . 2" This Side etfect 
was. however. easily treated with a small dose of 
fludroconisone. Possible mechanisms responsible 
ior the hyperkalemia include the inability of the 
distal renal tubules to respond to aldosterone t type 
IV renal tubular acidosis) and a decrease in the level 
of plasma renin caused by a depressed cellular 
activity of the juxtaglomerular system.30. 3i 
The risks of infection and posuransplantation 
lymphoproliferative diseases were similar with both 
FK 506 and CyA. Other advantages of FK 506 over 
CyA include a lower risk of the development of 
new-onset hypertension. the lack of gingival hyper-
plasia. and the lack of coarsening of facial features. 
Although the current study is limited by a lack of 
randomization and involves a different organ. it 
yields results similar to those of the randomized 
studies with liver and lung transplantation. In the 
EUTOoean multicenter trial. which consisted of 545 
primary liver recipients. the rate of patient and graft 
survl\ai was similar between FK 506 and CyA 
groups: however. patients receiving FK 506 had 
signiricamlv fewer episodes of acute. refractory 
acute. and chronic rejection.25 The multicenter trial 
in the C nited States consisting of 529 primary liver 
recipients reponed similar results.:3 The I-year 
actuarial survivals were similar between FK 506 and 
CyA arms. and patients receiving FK 506 had fewer 
episodes at acute. steroid-resistant. and refractory 
reJection. Our own randomized trial of FK 506 in 
lung transplantation.3: which involved 74 lung recip-
ients 1P~ received FK 506 and 30 CyA). reported the 
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same findings. The i-year survival was similar be-
tween the two groups: however. patients in the FK 
506 arm had significantly fewer episodes of acute 
and refractory rejection. 
In summary. FK 506 has proved to be an effective 
immunosuppressive agent in clinical cardiac trans-
plantation. The intermediate-term results indicate 
that the patient survival is similar with FK 506 and 
CyA immunosuppression. However, patients receiv-
ing FK 506 have fewer episodes of acute and 
refractory rejection. require less treatment for rejec-
tion. and need lower doses of maintenance steroids. 
Major side effects of FK 506 and CyA are similar. 
FK 506. therefore. is a useful drug in clinical heart 
transplantation. 
We thank Howard R. Davie. MD. and Alfred Cecchetti. 
MSc. for their advice on stiltistical methods. 
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Discussion 
Dr. Eric A. Rose (New York. N.r:). It is Clear that F]';' 
506 is a valuable addition to our armamentarium of 
immunosuppressive agents. It is at least equal to CyA as a 
maintenance immunosuppressive agent with regard to 
survival. and it is superior with regard to morbidities 
including gingival hyperplasia. hirsutism. and hyperten-
sion. 
I am concerned. however. about the claim that FK 506 
offers advantages over CyA-based immunosuppression 
with regard to the frequency and severity of acute rejec-
tion episodes. It must be pointed out. as Dr. Pham has 
mentioned. that this was not a blinded randomized trial 
and that enthusiasm for a new agent may often engender 
subtle therapeutic biases that may compensate the validity 
of seemingly significant findings. The manuscript de-
scribes the strategy of boosting FK 506 doses in the 
presence of histologically mild rejection episodes in the 
FK 500 group. In contrast. no comparable strategy of 
increasmg CyA doses in the control group IS described. 
This discrepancy raises the question that the lower fre-
quencv of refractory rejection and the higher ouantities of 
steroids used in the CyA-treated group were due to this 
difference in dosing strategy rather than mtnnsic differ-
ences between the two drugs. 
This report also shows that with regard to nephrotox-
icity and development of late graft atherosclerosis. FK 506 
offers no advantage over CyA. It remains clear that these 
two problems. particularly the latter. remain the Achilles 
heel of presently available immunosuppressl\e regImens. 
Perhaps the most impressive finding in thIS expenence 
is the successful treatment of rejection refractory to 
conventional treatment in 18 CyA-treated patients by 
sWllching to FK 506. The clinical imponance llt this 
observation cannot be overestimated and pro\10eS trans-
plant groups with a powerful new tool for an otherwise 
unmanageable problem. 
I have the following questions: 
Is a randomized maintenance immunosuppressIon trIal 
between these two agents planned tor nean transplant 
recipients? If not. is FK 506 the authors· immunosuppres-
sive agent of choice for mamtenance immunosuppressIOn' 
Can FK 506 and e,A be used m combmallon ) 
Could FK 506 be used to initially treat acute relection 
episodes III CyA-treated patients instead Ol ster01ds or 
anti-T-cell antibodies? 
Last. is the cost of this newly approved drug comparable 
with the cost of CyA".) 
The Joumal of ThoraCIC and 
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Dr. Aldo R. Castaneda (('t'lwilt'r. Switzer/and). Is this 
drug available for everybody. llr is it still a controlled 
substance. so to speak'! 
Dr. Pham. To answer Dr. Castaneda's question. this 
drug has been approved hy the Food and Drug Adminis-
tration tor usc in liver transplantation. However. we. as 
cardiac surgeons. can use this drug as an off-labeled drug. 
So it is available for cvcrybouy to try. 
Dr. Rose. with regard to the randomized trial. a multi-
center trial is going to be conducted in the United States. 
In Europe. single-center trials wmparing CyA and FK 506 
in heart transplantation have heen initiated. 
The second question was whether FK 506 was our 
immunosuppression of choice. The answer is yes. We 
prefer this medication over Cy.-\ tor all of the advantages 
that I ha\'e alluded to. Mainh·. it is easier to manage the 
FK 506-treated patients because there is less rejection 
and fewer side effects. Compared with CyA. FK 506 has 
fewer cosmetic side effects. su.:n g~ cushingoid features. 
hirsutism. and gingival hyperplasia . .-\s you know. after the 
patients recover from an acute disease. cosmetic issues 
become a real concern for them, FK 506. therefore. 
certainly has these additional advantages over CyA. 
The third question was whether FK 506 could be used 
in combination with CyA. In \ltTO. FK 506 and CyA are 
synergistic in their immunosupt.'TessiH: properties. Ho\\-
ever. as far as I know. nobody has tried to combine these 
medications in a clinical settin~K I suppose. because of the 
fear of renal toxicity and the complexitv of monitoring 
these [WO drug levels at the same time. . -
The b<t question was whe!~;?~ FI-: 50t) could he used 
initially to treat the rejection III the CyA-treated patient 
instead of steroids or anti-T-celi antibodies. The answer is 
yes. As we have learned over the past 5 years. there was a 
higher incidence of posttranspiantatlon lymphoprolifera-
live disease in patients who reQUire FK 506 rescue for 
rejection that was refractory to other immunosuppressive 
agents. Because of this problem. \\e are now more aggres-
sive in converting our patients to FK 506. We have 
aggressive Iv switched our CvA-treated patients to FK 506 
when they have relection. and we trv mtentionally not to 
treat them with multiple doses or steroids and antilym-
pholytic agents. 
Regarding the cost of this drug. I was told that this 
agent was as comparable 10 terms 01 cost to evA. but I do 
not know the details. 
My flnal comments are ttl CIJrIT\ one pomt Dr. Rose 
made in regard to the strateg\ l't r-oosting FK 506 doses 
in the presence at histolog.cal1\· mild rejection episodes. 
\Ve did the same with the CI.-\-treatcd patient if thc 
evA le\·ei was not considerec te' r>e optimal. Thereforc. 
the dOSing strategy is similar r-etween the two groups of 
paticnts. 
